Edition:
India

Kamada Ltd (KMDA.OQ)

KMDA.OQ on NASDAQ Stock Exchange Global Select Market

5.62USD
2:15am IST
Change (% chg)

$0.03 (+0.45%)
Prev Close
$5.60
Open
$5.55
Day's High
$5.62
Day's Low
$5.50
Volume
3,802
Avg. Vol
10,843
52-wk High
$8.55
52-wk Low
$3.75

Latest Key Developments (Source: Significant Developments)

Kamada Announces Collaboration With Hospitals To Evaluate Its Product For Preemption Of Type Of Graft-Versus-Host Disease
Thursday, 4 Jan 2018 

Jan 4 (Reuters) - Kamada Ltd ::KAMADA ANNOUNCES COLLABORATION WITH A CONSORTIUM OF PROMINENT HOSPITALS LED BY THE MOUNT SINAI HOSPITAL TO EVALUATE ITS ALPHA-1 ANTITRYPSIN PRODUCT FOR PREEMPTION OF STEROID REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE.KAMADA SAYS ANNOUNCED COLLABORATION WITH MOUNT SINAI ACUTE GVHD INTERNATIONAL CONSORTIUM.KAMADA LTD - RECEIVED EXCLUSIVE RIGHTS TO DEVELOP AND COMMERCIALIZE ALPHA-1 ANTITRYPSIN FOR PREEMPTION OF GVHD USING MAGIC BIOMARKERS.KAMADA SAYS STUDY OF ALPHA-1-ANTITRYPSIN WILL BE INITIATED IN Q1 OF 2018.KAMADA LTD - TOP-LINE RESULTS FROM ALPHA-1-ANTITRYPSIN STUDY ARE EXPECTED TO BE AVAILABLE IN SECOND HALF OF 2019.  Full Article

Kamada announces new supply agreement with international organization for KamRAB
Tuesday, 21 Nov 2017 

Nov 21 (Reuters) - Kamada Ltd :Kamada announces new supply agreement with international organization for KamRAB for post-exposure prophylaxis against rabies infection.Kamada Ltd - the ‍three-year supply agreement will extend through 2020, and is expected to generate revenues for Kamada of approximately $13 million​.  Full Article

Kamada and ‍Chiesi Farmaceutici terminate European distribution agreement for inhaled alpha-1 antitrypsin therapy
Monday, 20 Nov 2017 

Nov 20 (Reuters) - Kamada Ltd ::Kamada Ltd - Co, ‍chiesi Farmaceutici S.P.A. mutually agree to terminate European distribution agreement for inhaled alpha-1 antitrypsin therapy.Kamada Ltd - ‍Kamada now maintains full, worldwide commercial rights to its inhaled aat​.Kamada - ‍ no financial implications related to termination of agreement for inhaled alpha-1 antitrypsin therapy.  Full Article

Kamada and Kedrion seek FDA approval of human rabies immunoglobulin
Thursday, 1 Sep 2016 

Kamada Ltd : Kamada and Kedrion seek FDA approval of human rabies immunoglobulin as a post-exposure treatment .Companies planning for decision from FDA in mid-2017.  Full Article

Kamada meets primary endpoint of U.S. Phase 2 study of inhaled Alpha-1 Antitrypsin
Tuesday, 30 Aug 2016 

Kamada Ltd : Kamada meets primary endpoint of U.S. Phase 2 study of inhaled Alpha-1 Antitrypsin for the treatment of Alpha-1 Antitrypsin deficiency . There were no differences seen in safety parameters between placebo and treatment groups .To utilize results to design U.S. study and support responses to EMA regarding Co's marketing authorization application for inhaled AAT.  Full Article

Kamada reports Q2 adjusted loss per share $0.11
Tuesday, 2 Aug 2016 

Kamada Ltd : Kamada reports financial results for the second quarter and first six months of 2016 . Q2 loss per share $0.04 . Sees FY 2017 sales $100 million . Q2 revenue $19.1 million versus $19.2 million .Sees FY 2016 revenue $75 million to $80 million.  Full Article

Shire and Kamada announce FDA approval of an expanded label for GLASSIA
Wednesday, 15 Jun 2016 

Shire PLC : Shire and Kamada announce FDA approval of expanded label for self-infusion of GLASSIA for the treatment of emphysema due to severe AAT deficiency . Serious adverse reaction observed during clinical trials was exacerbation of chronic obstructive pulmonary disease .Infusion of GLASSIA for the treatment of emphysema due to severe AAT deficiency.  Full Article

BRIEF-Kamada Announces Data From Phase 2 Clinical Trial Of Intravenous Alpha-1 Antitrypsin Treatment For Prevention Of Lung Transplant Rejection

* KAMADA ANNOUNCES INTERIM RESULTS FROM PHASE 2 CLINICAL TRIAL OF INTRAVENOUS ALPHA-1 ANTITRYPSIN TREATMENT FOR PREVENTION OF LUNG TRANSPLANT REJECTION